Purchasing Time

Anupam Rasayan’s acquisition of a controlling stake in Bliss GVS Pharma is being framed as a straightforward case of forward integration. A specialty chemicals business moving closer to finished pharmaceutical formulations sounds logical on paper. One side understands chemistry and process manufacturing. The other owns dosage capabilities, regulatory approvals, brands, and export relationships. The industrial logic is easy to understand, which is precisely why the deal deserves closer examination.